Skip to content

Antecubital Versus Femoral Approach for Adrenal Venous Sampling

Antecubital Versus Femoral Approach for Adrenal Venous Sampling: A Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06029803
Acronym
AFAVS
Enrollment
154
Registered
2023-09-08
Start date
2022-04-01
Completion date
2023-11-30
Last updated
2023-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperaldosteronism

Keywords

Adrenal venous sampling, Hyperaldosteronism, Antecubital approach, Femoral approach

Brief summary

Subtype diagnosis is crucial for the treatment of primary aldosteronism (PA), which conducts the appropriate treatment strategy. Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. At present, almost all medical centers use the femoral vein approach for AVS, and most studies report that the success rate is 30%-80%. Our research team is the first in the world to conduct AVS via an antecubital approach. The aim of this study is to compare the success rate and safety of AVS via antecubital and femoral approach.

Detailed description

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account for 95% to 98% of PA. Subtype diagnosis is crucial for the treatment of primary aldosteronism, which conducts the appropriate treatment strategy. Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. At present, almost all medical centers use the femoral vein approach for AVS, and most studies report that the success rate is 30%-80%.How to improve the success rate of AVS has been a hot topic in the field of primary aldosteronism. Our research team is the first in the world to conduct AVS via an antecubital approach. The previous study found that the success rate of AVS via this approach can reach to 88.0%, with a low incidence of complications. In this study, patients with primary aldosteronism who meet the indications of AVS will be randomly assigned to antecubital approach group and femoral approach group. Clinical, laboratory and examination data will be recorded and the success rate and safety of AVS via antecubital and femoral approach will be compared.

Interventions

PROCEDUREAdrenal Venous Sampling via Antecubital Approach

Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.

PROCEDUREAdrenal Venous Sampling via Femoral Approach

Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Aged from 18 to 60 with no limits in sex; 2. Patients with confirmed primary aldosteronism; 3. Patients or their legal representatives sign written informed consent approved by the ethics committee

Exclusion criteria

1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months; 2. An estimated glomerular filtration rate \<45 ml/min/1.73 m2, or serum creatinine \>176 μmol/L; 3. Patients who refuse adrenalectomy; 4. suspected of having an adrenocortical carcinoma; 5. allergy to contrast agent; 6. pregnant, nursing, or planning to become pregnant

Design outcomes

Primary

MeasureTime frameDescription
The success rate of bilateral adrenal venous samplingAt AVS procedureSuccessful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)

Secondary

MeasureTime frameDescription
The success rate of right adrenal venous samplingAt AVS procedureSuccessful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
Selection of intraoperative catheterAt AVS procedureCatheter selection
Time of the procedureAt AVS procedureTime of the procedure
The success rate of left adrenal venous samplingAt AVS procedureSuccessful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
The contrast agent dosageAt AVS procedureThe contrast agent dosage
the incidence of complications1 week after AVS procedureComplications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)
the cost of the procedureAt AVS procedurethe cost of the procedure
Time of fluoroscopyAt AVS procedureTime of fluoroscopy

Countries

China

Contacts

Primary ContactHui Dong, MD
donghui666@sina.com86-010-88322387

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026